Ország: Kanada
Nyelv: angol
Forrás: Health Canada
METHOCARBAMOL; IBUPROFEN
VITA HEALTH PRODUCTS INC
M03BA53
METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS
500MG; 200MG
TABLET
METHOCARBAMOL 500MG; IBUPROFEN 200MG
ORAL
18/27/40/50/80
OTC
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0248961001; AHFS:
APPROVED
2011-01-20
PRODUCT MONOGRAPH PLATINUM MUSCLE AND BACK PAIN RELIEF 500 MG METHOCARBAMOL AND 200 MG IBUPROFEN CAPLETS THERAPEUTIC CLASSIFICATION MUSCLE RELAXANT / ANALGESIC VITA HEALTH PRODUCTS INC. DATE OF PREPARATION: 150 BEGHIN AVENUE, January 17, 2011 WINNIPEG, MB CANADA, R2J 3W2 CONTROL NO.: 128349 2 TABLE OF CONTENTS Page CLINICAL PHARMACOLOGY.............................................................................................3 INDICATIONS: ...............................................................................................................6 CONTRAINDICATIONS .....................................................................................................6 WARNINGS: .................................................................................................................7 PRECAUTIONS .............................................................................................................10 DRUG INTERACTIONS ...................................................................................................12 ADVERSE REACTIONS..................................................................................................13 SYMPTOMS AND TREATMENT OF OVERDOSE ...............................................................15 DOSAGE AND ADMINISTRATION...................................................................................16 PHARMACEUTICAL INFORMATION.................................................................................16 COMPOSITION ............................................................................................................19 AVAILABILITY OF DOSAGE FORMS................................................................................19 INFORMATION FOR THE CONSUMER .............................................................................20 PHARMACOLOGY ..............................................................................................22 CLINICAL TRIALS .......................................................................................... Olvassa el a teljes dokumentumot